Secondary: Bridgepoint acquires majority stake in PharmaZell
Munich — International private equity investor Bridgepoint acquires a majority stake in PharmaZell from DPE Deutsche Private Equity and Maxburg Capital Partners. The parties have agreed not to disclose the purchase price.
PharmaZell is a leading independent manufacturer of Active Pharmaceutical Ingredients (API) in the highly stable and specialized API market. There, the company has a diversified portfolio of more than 70 active ingredients and is an industry leader in a full range of products for the treatment of respiratory, inflammatory and liver diseases driven by lifestyle changes. Many of the company’s products require special treatment processes and/or technologies. PharmaZell, headquartered in Raubling (near Munich), operates four state-of-the-art production and R&D sites in Germany, Italy and India and employs over 900 people worldwide.
Bridgepoint manages more than €29 billion in assets provided by global investors. These include public and private pension funds, asset managers, family offices, independent authorities and insurance companies around the world.
Advisors PharmaZell: P+P Pöllath + Partners advised the management around CEO Oliver Bolzern.
Dr. Benedikt Hohaus (Partner, Lead Partner, MPP, M&A/Private Equity)
Dr. Roman Stenzel (Counsel, MPP, M&A/Private Equity)
Silke Bandener (Associate, MPP, M&A/Private Equity, all Munich)